<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02712554</url>
  </required_header>
  <id_info>
    <org_study_id>CLCT-007</org_study_id>
    <nct_id>NCT02712554</nct_id>
  </id_info>
  <brief_title>A Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo and Active-Controlled, Crossover Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charleston Laboratories, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charleston Laboratories, Inc</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the abuse potential of CL-108 tablets, including the
      abuse deterrent effects of promethazine, following oral administration, relative to
      hydrocodone/acetaminophen (APAP) tablets and placebo in non-dependent, recreational opioid
      users.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the abuse potential of CL-108 tablets, including the
      abuse deterrent effects of promethazine, following oral administration, relative to
      hydrocodone/acetaminophen (APAP) tablets and placebo in non-dependent, recreational opioid
      users; to assess the cognitive and behavioral effects of CL-108 tablets following oral
      administration relative to hydrocodone/APAP tablets and placebo in non-dependent,
      recreational opioid users; and to assess the safety of orally administered CL-108 tablets
      relative to hydrocodone/APAP tablets and placebo in non-dependent, recreational opioid users.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Effects: Maximum Effect (Emax) and Minimum Effect (Emin) of High Visual Analog Scale (VAS) in Dose Selection Phase</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours (post-dose)</time_frame>
    <description>High VAS measures the positive effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so'). For VAS assessment, pre-dose (baseline) value was subtracted from each post-dose value prior to calculation of the pharmacodynamic (PD) parameter. Emax is the largest effect score and Emin is the smallest effect score between 0 to 24 hours post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Effects: Emax of Any Effects VAS in Dose Selection Phase</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours (post-dose)</time_frame>
    <description>Any drug effects VAS measures other subjective effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so'). Emax is the largest effect score between 0 (pre-dose) to 24 hours post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Emax of Drug Liking VAS in Treatment Phase</measure>
    <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8 and 24 hours</time_frame>
    <description>Drug liking VAS is the measure of balance of effects that assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 millimeter (mm) bipolar (VAS) anchored in the center with a neutral anchor of 'neither like nor dislike' (score of 50 mm), on the left with 'strong disliking' (score of 0 mm) and on the right with 'strong liking' (score of 100 mm). Emax is the largest effect score between 0.5 to 24 hours post-dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events in Dose Selection Phase</measure>
    <time_frame>Up to visit 3 (Follow up)</time_frame>
    <description>AE=Adverse Event. SAE=Serious adverse event. TEAE=Treatment-emergent adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Balance of Effects: Emin of Drug Liking VAS in Treatment Phase</measure>
    <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours</time_frame>
    <description>Drug liking VAS is the measure of balance of effects that assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 millimeter (mm) bipolar (VAS) anchored in the center with a neutral anchor of 'neither like nor dislike' (score of 50 mm), on the left with 'strong disliking' (score of 0 mm) and on the right with 'strong liking' (score of 100 mm). Emin is the smallest effect score between 0.5 to 8 hours post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Balance of Effects: Time-averaged Area Under the Effect Curve (TA_AUE) of Drug Liking VAS in Treatment Phase</measure>
    <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours</time_frame>
    <description>TA_AUE is AUE0-8hr divided by time from dosing to the actual time of the 8-hour post-dose assessment using the trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Balance of Effects: Emax and Emin of Overall Drug Liking VAS in Treatment Phase</measure>
    <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours</time_frame>
    <description>Overall drug liking VAS is the measure of balance of effects that assesses the participant's global perception of drug liking (that is, effects over the whole course of the drug experience including any carryover effects). A 100 mm bipolar VAS is used to assess response based on a score ranging from 0 mm to 100 mm (0 mm = 'strong disliking', 50 mm = 'neither like nor dislike', and 100 mm = 'strong liking'). Emax is the largest effect score and Emin is the smallest effect score between 0 to 8 hours post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Balance of Effects: Emax and Emin of Take Drug Again VAS in Treatment Phase</measure>
    <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours</time_frame>
    <description>Take drug again VAS is the measure of balance of effects. It is a subjective assessment of the degree to which a participant would desire to take the drug again if given the opportunity. It is presented on a 100 mm bipolar VAS with score ranging from 0 mm to 100 mm (0 mm = 'definitely not', 50 mm = 'do not care', and 100 mm = 'definitely so'). Emax is the largest effect score and Emin is the smallest effect score between 0 to 8 hours post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Effects: Emax of High VAS in Treatment Phase</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours (post-dose)</time_frame>
    <description>High VAS measures the positive effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so'). For VAS assessment, pre-dose (baseline) value was subtracted from each post-dose value prior to calculation of the pharmacodynamic (PD) parameter. Emax is the largest effect score between 0 to 8 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Effects: TA_AUE of High VAS in Treatment Phase</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours (post-dose)</time_frame>
    <description>TA_AUE is AUE0-8hr divided by time from dosing to the actual time of the 8-hour post-dose assessment using the trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Effects: Emax of Good Effects VAS in Treatment Phase</measure>
    <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours</time_frame>
    <description>Good drug effects VAS measures the positive effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so'). Emax is the largest effect score between 0.5 to 8 hours post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Effects: TA_AUE of Good Effects VAS in Treatment Phase</measure>
    <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours</time_frame>
    <description>TA_AUE is AUE0-8hr divided by time from dosing to the actual time of the 8-hour post-dose assessment using the trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative Effects: Emax of Bad Effects VAS in Treatment Phase</measure>
    <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours</time_frame>
    <description>Bad effects VAS measures the negative effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so'). Emax is the largest effect score between 0.5 to 8 hrs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative Effects: TA_AUE of Bad Effects VAS in Treatment Phase</measure>
    <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours</time_frame>
    <description>TA_AUE is AUE0-8hr divided by time from dosing to the actual time of the 8-hour post-dose assessment using the trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedative and Other Effects: Emin of Alertness/Drowsiness VAS in Treatment Phase</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours (post-dose)</time_frame>
    <description>Alertness/Drowsiness VAS measures the sedative effects. It is scored using a 100 mm bipolar VAS anchored in the center with a neutral anchor of 'neither drowsy nor alert' (score of 50 mm), on the left with 'very drowsy' (score of 0 mm) and on the right with 'very alert' (score of 100 mm). Alertness/Drowsiness VAS was calculated by subtracting pre-dose (baseline) value from each post-dose value. Emin is the smallest effect score between 0 to 8 hours post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedative and Other Effects: TA_AUE of Alertness/Drowsiness VAS in Treatment Phase</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours (post-dose)</time_frame>
    <description>Alertness/Drowsiness VAS measures the sedative effects. It is scored using a 100 mm bipolar VAS anchored in the center with a neutral anchor of 'neither drowsy nor alert' (score of 50 mm), on the left with 'very drowsy' (score of 0 mm) and on the right with 'very alert' (score of 100 mm). Alertness/Drowsiness VAS was calculated by subtracting pre-dose (baseline) value from each post-dose value. TA_AUE is AUE0-8hr divided by time from dosing to the actual time of the 8-hour post-dose assessment using trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedative and Other Effects: Emax of Any Effects VAS in Treatment Phase</measure>
    <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours</time_frame>
    <description>Any drug effects VAS measures other subjective effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so'). Emax is the largest effect score between 0.5 to 8 hours post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedative and Other Effects: TA_AUE of Any Effects VAS in Treatment Phase</measure>
    <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours</time_frame>
    <description>TA_AUE is AUE0-8hr divided by time from dosing to the actual time of the 8-hour post-dose assessment using the trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Measures: Change From Baseline in Choice Reaction Time (CRT) in Treatment Phase</measure>
    <time_frame>0 (Baseline, pre-dose), 1, 2, 4, 8 and 24 hours (post-dose)</time_frame>
    <description>CRT is a computerized 5-choice reaction time test in which the subject must press and hold down a touchscreen button at the bottom of the screen. A yellow spot appeared inside one of 5 yellow circles at the top of the screen. Subjects were to respond to the spot as quickly as they could by letting go of the button and touching the circle where the yellow spot appeared. This was repeated for 30 trials. Lower scores indicate better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Errors (Any Errors) in CRT Test in Treatment Phase</measure>
    <time_frame>0 (Baseline, pre-dose), 1, 2, 4, 8 and 24 hours (post-dose)</time_frame>
    <description>CRT is a computerized 5-choice reaction time test in which the subject must press and hold down a touchscreen button at the bottom of the screen. A yellow spot appeared inside one of 5 yellow circles at the top of the screen. Subjects were to respond to the spot as quickly as they could by letting go of the button and touching the circle where the yellow spot appeared. This was repeated for 30 trials. Lower scores indicate better performance. CRT also measures error scores and response accuracy. Any Errors is a combination of incorrect location errors, inaccurate response errors, no response errors, and premature errors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupillometry: Maximum Pupil Constriction (MPC)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours (post-dose)</time_frame>
    <description>Pupillometry assessments measured change in pupil size (miosis) as an indicator of opioid pharmacological properties. Pupil diameter was measured using electronic pupillometer. Measurements were collected under mesopic lighting conditions. For each subject, every effort was made to use the same eye for all assessments throughout the study. MPC is calculated as smallest observed pupil diameter - baseline pupil diameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupillometry: TA_AUE of MPC in Treatment Phase</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours (post-dose)</time_frame>
    <description>TA_AUE is AUE0-8hr divided by time from dosing to the actual time of the 8-hour post-dose assessment using the trapezoidal rule.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Pain</condition>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>Treatment A:CL-108 22.5mg/975mg/37.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B:CL-108 37.5mg/1625mg/62.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C:M366 22.5mg/975mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>M366 22.5 mg/975 mg tablet by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D: M366 37.5mg/1625mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>M366 37.5 mg/1625 mg tablet by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment E: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 0 mg tablet by mouth</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CL-108</intervention_name>
    <description>7.5 mg/325 mg/12.5 mg tablet</description>
    <arm_group_label>Treatment A:CL-108 22.5mg/975mg/37.5mg</arm_group_label>
    <arm_group_label>Treatment B:CL-108 37.5mg/1625mg/62.5mg</arm_group_label>
    <other_name>Low-dose CL-108 and High-dose CL-108</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M366</intervention_name>
    <description>7.5 mg/325 mg tablet</description>
    <arm_group_label>Treatment C:M366 22.5mg/975mg</arm_group_label>
    <arm_group_label>Treatment D: M366 37.5mg/1625mg</arm_group_label>
    <other_name>Low-dose M366 and High-dose M366</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Treatment E: Placebo</arm_group_label>
    <other_name>0 mg tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI within 18.0 to 33.0 kg/m2, inclusive (minimum weight of 50.0 kg at Screening)

          -  Healthy, as determined by no clinically significant medical history, physical
             examination findings, 12-lead ECG findings, vital signs measurements, and laboratory
             results at screening, as judged by the investigator

          -  Current opioid users who had used oral opioids for recreational (non-therapeutic)
             purposes, at least 10 times in the past year

        Exclusion Criteria:

          -  Drug or alcohol dependence within the last 12 months (except nicotine)

          -  Subjects who had ever been in treatment for substance use disorders (except smoking
             cessation

          -  History of presence of any clinically significant cardiac, neurologic, pulmonary,
             psychiatric, endocrine, hematologic, hepatic, immunologic, metabolic, urologic,
             dermatologic, renal, or other major disease at screening, which in the opinion of the
             investigator, would have jeopardized the safety of the subject or the validity of the
             study results

          -  History or presence of hypotension, judged to be clinically significant based on
             investigator judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard P Schachtel, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Charleston Laboratories</affiliation>
  </overall_official>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 15, 2016</study_first_submitted>
  <study_first_submitted_qc>March 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2016</study_first_posted>
  <results_first_submitted>November 14, 2016</results_first_submitted>
  <results_first_submitted_qc>October 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2019</results_first_posted>
  <last_update_submitted>October 11, 2019</last_update_submitted>
  <last_update_submitted_qc>October 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Nausea</keyword>
  <keyword>Vomiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Total 12 subjects were enrolled and completed the Dose Selection phase. Subjects randomized to the Treatment phase were 40 and all of them received at least 1 dose of study drug, and 37 subjects completed the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A (Dose Selection Phase): CL-108 or Placebo</title>
          <description>Treatment AA: CL-108 15 mg/650 mg/25 mg tablet by mouth
Treatment BB: CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth
Treatment CC: CL-108 30 mg/1300 mg/50 mg tablet by mouth
Treatment DD: CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth
Treatment EE: Placebo 0 mg tablet by mouth</description>
        </group>
        <group group_id="P2">
          <title>Part B (Treatment Phase): CL-108, M366 and Placebo</title>
          <description>Treatment A (low-dose): CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth
Treatment B (high-dose): CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth
Treatment C (low-dose): M366 22.5 mg/975 mg tablet by mouth
Treatment D (high-dose): M366 37.5 mg/1625 mg tablet by mouth
Treatment E: Placebo 0 mg tablet by mouth</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A: Dose Selection Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0">Subjects who participated in Dose Selection Phase were not eligible to participate in Part B.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part B: Qualification Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Drug Discrimination Failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B: Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part A (Dose Selection Phase): CL-108 or Placebo</title>
          <description>Treatment AA: CL-108 15 mg/650 mg/25 mg tablet by mouth
Treatment BB: CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth
Treatment CC: CL-108 30 mg/1300 mg/50 mg tablet by mouth
Treatment DD: CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth
Treatment EE: Placebo 0 mg tablet by mouth</description>
        </group>
        <group group_id="B2">
          <title>Part B (Treatment Phase): CL-108, M366 and Placebo</title>
          <description>Treatment A (low-dose): CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth
Treatment B (high-dose): CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth
Treatment C (low-dose): M366 22.5 mg/975 mg tablet by mouth
Treatment D (high-dose): M366 37.5 mg/1625 mg tablet by mouth
Treatment E: Placebo 0 mg tablet by mouth</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjective Effects: Maximum Effect (Emax) and Minimum Effect (Emin) of High Visual Analog Scale (VAS) in Dose Selection Phase</title>
        <description>High VAS measures the positive effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so'). For VAS assessment, pre-dose (baseline) value was subtracted from each post-dose value prior to calculation of the pharmacodynamic (PD) parameter. Emax is the largest effect score and Emin is the smallest effect score between 0 to 24 hours post-dose.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours (post-dose)</time_frame>
        <population>Safety population.
Parameters were not calculated for subjects who experienced emesis within the first 3 hours post-dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment AA: CL-108 15 mg/650 mg/25 mg</title>
            <description>CL-108 15 mg/650 mg/25 mg tablet by mouth</description>
          </group>
          <group group_id="O2">
            <title>Treatment BB: CL-108 22.5 mg/975 mg/37.5 mg</title>
            <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
          </group>
          <group group_id="O3">
            <title>Treatment CC: CL-108 30 mg/1300 mg/50 mg</title>
            <description>CL-108 30 mg/1300 mg/50 mg tablet by mouth</description>
          </group>
          <group group_id="O4">
            <title>Treatment DD: CL-108 37.5 mg/1625 mg/62.5 mg</title>
            <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
          </group>
          <group group_id="O5">
            <title>Treatment EE: Placebo</title>
            <description>Placebo 0 mg tablet by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Effects: Maximum Effect (Emax) and Minimum Effect (Emin) of High Visual Analog Scale (VAS) in Dose Selection Phase</title>
          <description>High VAS measures the positive effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so'). For VAS assessment, pre-dose (baseline) value was subtracted from each post-dose value prior to calculation of the pharmacodynamic (PD) parameter. Emax is the largest effect score and Emin is the smallest effect score between 0 to 24 hours post-dose.</description>
          <population>Safety population.
Parameters were not calculated for subjects who experienced emesis within the first 3 hours post-dose.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Emax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" spread="21.21"/>
                    <measurement group_id="O2" value="42.0" spread="21.21"/>
                    <measurement group_id="O3" value="75.5" spread="34.65"/>
                    <measurement group_id="O4" value="94.0"/>
                    <measurement group_id="O5" value="2.3" spread="4.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="4.24"/>
                    <measurement group_id="O2" value="23.5" spread="3.54"/>
                    <measurement group_id="O3" value="42.0" spread="11.31"/>
                    <measurement group_id="O4" value="7.0"/>
                    <measurement group_id="O5" value="60.8" spread="20.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjective Effects: Emax of Any Effects VAS in Dose Selection Phase</title>
        <description>Any drug effects VAS measures other subjective effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so'). Emax is the largest effect score between 0 (pre-dose) to 24 hours post-dose.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours (post-dose)</time_frame>
        <population>Safety population.
Parameters were not calculated for subjects who experienced emesis within the first 3 hours post-dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment AA: CL-108 15 mg/650 mg/25 mg</title>
            <description>CL-108 15 mg/650 mg/25 mg tablet by mouth</description>
          </group>
          <group group_id="O2">
            <title>Treatment BB: CL-108 22.5 mg/975 mg/37.5 mg</title>
            <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
          </group>
          <group group_id="O3">
            <title>Treatment CC: CL-108 30 mg/1300 mg/50 mg</title>
            <description>CL-108 30 mg/1300 mg/50 mg tablet by mouth</description>
          </group>
          <group group_id="O4">
            <title>Treatment DD: CL-108 37.5 mg/1625 mg/62.5 mg</title>
            <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
          </group>
          <group group_id="O5">
            <title>Treatment EE: Placebo</title>
            <description>Placebo 0 mg tablet by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Effects: Emax of Any Effects VAS in Dose Selection Phase</title>
          <description>Any drug effects VAS measures other subjective effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so'). Emax is the largest effect score between 0 (pre-dose) to 24 hours post-dose.</description>
          <population>Safety population.
Parameters were not calculated for subjects who experienced emesis within the first 3 hours post-dose.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.0" spread="19.80"/>
                    <measurement group_id="O2" value="48.5" spread="26.16"/>
                    <measurement group_id="O3" value="75.0" spread="35.36"/>
                    <measurement group_id="O4" value="94.0"/>
                    <measurement group_id="O5" value="4.3" spread="5.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Emax of Drug Liking VAS in Treatment Phase</title>
        <description>Drug liking VAS is the measure of balance of effects that assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 millimeter (mm) bipolar (VAS) anchored in the center with a neutral anchor of 'neither like nor dislike' (score of 50 mm), on the left with 'strong disliking' (score of 0 mm) and on the right with 'strong liking' (score of 100 mm). Emax is the largest effect score between 0.5 to 24 hours post-dose.</description>
        <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8 and 24 hours</time_frame>
        <population>Intended to treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 22.5 mg/975 mg/37.5 mg</title>
            <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 37.5 mg/1625 mg/62.5 mg</title>
            <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: M366 22.5 mg/975 mg</title>
            <description>M366 22.5 mg/975 mg tablet by mouth</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: M366 37.5 mg/1625 mg</title>
            <description>M366 37.5 mg/1625 mg tablet by mouth</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: Placebo</title>
            <description>Placebo 0 mg tablet by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Emax of Drug Liking VAS in Treatment Phase</title>
          <description>Drug liking VAS is the measure of balance of effects that assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 millimeter (mm) bipolar (VAS) anchored in the center with a neutral anchor of 'neither like nor dislike' (score of 50 mm), on the left with 'strong disliking' (score of 0 mm) and on the right with 'strong liking' (score of 100 mm). Emax is the largest effect score between 0.5 to 24 hours post-dose.</description>
          <population>Intended to treat (ITT) population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3" spread="14.68"/>
                    <measurement group_id="O2" value="81.4" spread="13.10"/>
                    <measurement group_id="O3" value="74.4" spread="13.75"/>
                    <measurement group_id="O4" value="79.8" spread="13.07"/>
                    <measurement group_id="O5" value="54.5" spread="9.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.2344</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.4737</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events in Dose Selection Phase</title>
        <description>AE=Adverse Event. SAE=Serious adverse event. TEAE=Treatment-emergent adverse event.</description>
        <time_frame>Up to visit 3 (Follow up)</time_frame>
        <population>Safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Dose Selection Phase</title>
            <description>Naloxone 0.2 mg bolus intravenously followed by a 10 mL saline flush
CL-108 15 mg/650 mg/25 mg
CL-108 22.5 mg/975 mg/37.5 mg
CL-108 30 mg/1300 mg/50 mg
CL-108 37.5 mg/1625 mg/62.5 mg
Placebo 0 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events in Dose Selection Phase</title>
          <description>AE=Adverse Event. SAE=Serious adverse event. TEAE=Treatment-emergent adverse event.</description>
          <population>Safety population.</population>
          <units>Event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total number of AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Number of TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of AEs leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Balance of Effects: Emin of Drug Liking VAS in Treatment Phase</title>
        <description>Drug liking VAS is the measure of balance of effects that assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 millimeter (mm) bipolar (VAS) anchored in the center with a neutral anchor of 'neither like nor dislike' (score of 50 mm), on the left with 'strong disliking' (score of 0 mm) and on the right with 'strong liking' (score of 100 mm). Emin is the smallest effect score between 0.5 to 8 hours post-dose.</description>
        <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 22.5 mg/975 mg/37.5 mg</title>
            <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 37.5 mg/1625 mg/62.5 mg</title>
            <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: M366 22.5 mg/975 mg</title>
            <description>M366 22.5 mg/975 mg tablet by mouth</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: M366 37.5 mg/1625 mg</title>
            <description>M366 37.5 mg/1625 mg tablet by mouth</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: Placebo</title>
            <description>Placebo 0 mg tablet by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Balance of Effects: Emin of Drug Liking VAS in Treatment Phase</title>
          <description>Drug liking VAS is the measure of balance of effects that assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 millimeter (mm) bipolar (VAS) anchored in the center with a neutral anchor of 'neither like nor dislike' (score of 50 mm), on the left with 'strong disliking' (score of 0 mm) and on the right with 'strong liking' (score of 100 mm). Emin is the smallest effect score between 0.5 to 8 hours post-dose.</description>
          <population>ITT population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.0" spread="3.16"/>
                    <measurement group_id="O2" value="46.6" spread="12.16"/>
                    <measurement group_id="O3" value="44.8" spread="11.67"/>
                    <measurement group_id="O4" value="46.5" spread="12.96"/>
                    <measurement group_id="O5" value="47.1" spread="11.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Balance of Effects: Time-averaged Area Under the Effect Curve (TA_AUE) of Drug Liking VAS in Treatment Phase</title>
        <description>TA_AUE is AUE0-8hr divided by time from dosing to the actual time of the 8-hour post-dose assessment using the trapezoidal rule.</description>
        <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 22.5 mg/975 mg/37.5 mg</title>
            <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 37.5 mg/1625 mg/62.5 mg</title>
            <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: M366 22.5 mg/975 mg</title>
            <description>M366 22.5 mg/975 mg tablet by mouth</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: M366 37.5 mg/1625 mg</title>
            <description>M366 37.5 mg/1625 mg tablet by mouth</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: Placebo</title>
            <description>Placebo 0 mg tablet by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Balance of Effects: Time-averaged Area Under the Effect Curve (TA_AUE) of Drug Liking VAS in Treatment Phase</title>
          <description>TA_AUE is AUE0-8hr divided by time from dosing to the actual time of the 8-hour post-dose assessment using the trapezoidal rule.</description>
          <population>ITT population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.071" spread="10.4456"/>
                    <measurement group_id="O2" value="13.772" spread="10.6773"/>
                    <measurement group_id="O3" value="9.773" spread="12.4254"/>
                    <measurement group_id="O4" value="11.162" spread="12.8093"/>
                    <measurement group_id="O5" value="1.183" spread="5.0571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Balance of Effects: Emax and Emin of Overall Drug Liking VAS in Treatment Phase</title>
        <description>Overall drug liking VAS is the measure of balance of effects that assesses the participant's global perception of drug liking (that is, effects over the whole course of the drug experience including any carryover effects). A 100 mm bipolar VAS is used to assess response based on a score ranging from 0 mm to 100 mm (0 mm = 'strong disliking', 50 mm = 'neither like nor dislike', and 100 mm = 'strong liking'). Emax is the largest effect score and Emin is the smallest effect score between 0 to 8 hours post-dose.</description>
        <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 22.5 mg/975 mg/37.5 mg</title>
            <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 37.5 mg/1625 mg/62.5 mg</title>
            <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: M366 22.5 mg/975 mg</title>
            <description>M366 22.5 mg/975 mg tablet by mouth</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: M366 37.5 mg/1625 mg</title>
            <description>M366 37.5 mg/1625 mg tablet by mouth</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: Placebo</title>
            <description>Placebo 0 mg tablet by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Balance of Effects: Emax and Emin of Overall Drug Liking VAS in Treatment Phase</title>
          <description>Overall drug liking VAS is the measure of balance of effects that assesses the participant's global perception of drug liking (that is, effects over the whole course of the drug experience including any carryover effects). A 100 mm bipolar VAS is used to assess response based on a score ranging from 0 mm to 100 mm (0 mm = 'strong disliking', 50 mm = 'neither like nor dislike', and 100 mm = 'strong liking'). Emax is the largest effect score and Emin is the smallest effect score between 0 to 8 hours post-dose.</description>
          <population>ITT population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Emax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.4" spread="17.77"/>
                    <measurement group_id="O2" value="75.8" spread="17.16"/>
                    <measurement group_id="O3" value="65.2" spread="17.89"/>
                    <measurement group_id="O4" value="71.1" spread="16.81"/>
                    <measurement group_id="O5" value="52.2" spread="8.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.2" spread="17.07"/>
                    <measurement group_id="O2" value="66.7" spread="19.96"/>
                    <measurement group_id="O3" value="57.2" spread="18.85"/>
                    <measurement group_id="O4" value="59.2" spread="18.50"/>
                    <measurement group_id="O5" value="48.7" spread="9.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment C (low-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment D (high-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment A (low-dose CL-108) - Treatment C (low-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.1267</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment B (high-dose CL-108) - Treatment D (high-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.1767</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment A (low-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment B (high-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emin: Treatment C (low-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0119</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emin: Treatment D (high-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0025</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Emin: Treatment A (low-dose CL-108) - Treatment C (low-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.1679</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Emin: Treatment B (high-dose CL-108) - Treatment D (high-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0318</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emin: Treatment A (low-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Balance of Effects: Emax and Emin of Take Drug Again VAS in Treatment Phase</title>
        <description>Take drug again VAS is the measure of balance of effects. It is a subjective assessment of the degree to which a participant would desire to take the drug again if given the opportunity. It is presented on a 100 mm bipolar VAS with score ranging from 0 mm to 100 mm (0 mm = 'definitely not', 50 mm = 'do not care', and 100 mm = 'definitely so'). Emax is the largest effect score and Emin is the smallest effect score between 0 to 8 hours post-dose.</description>
        <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 22.5 mg/975 mg/37.5 mg</title>
            <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 37.5 mg/1625 mg/62.5 mg</title>
            <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: M366 22.5 mg/975 mg</title>
            <description>M366 22.5 mg/975 mg tablet by mouth</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: M366 37.5 mg/1625 mg</title>
            <description>M366 37.5 mg/1625 mg tablet by mouth</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: Placebo</title>
            <description>Placebo 0 mg tablet by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Balance of Effects: Emax and Emin of Take Drug Again VAS in Treatment Phase</title>
          <description>Take drug again VAS is the measure of balance of effects. It is a subjective assessment of the degree to which a participant would desire to take the drug again if given the opportunity. It is presented on a 100 mm bipolar VAS with score ranging from 0 mm to 100 mm (0 mm = 'definitely not', 50 mm = 'do not care', and 100 mm = 'definitely so'). Emax is the largest effect score and Emin is the smallest effect score between 0 to 8 hours post-dose.</description>
          <population>ITT population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Emax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6" spread="18.98"/>
                    <measurement group_id="O2" value="75.2" spread="18.49"/>
                    <measurement group_id="O3" value="68.9" spread="19.89"/>
                    <measurement group_id="O4" value="71.3" spread="20.51"/>
                    <measurement group_id="O5" value="51.1" spread="12.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.4" spread="19.85"/>
                    <measurement group_id="O2" value="69.3" spread="21.07"/>
                    <measurement group_id="O3" value="60.9" spread="21.19"/>
                    <measurement group_id="O4" value="61.9" spread="20.68"/>
                    <measurement group_id="O5" value="47.5" spread="12.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment C (low-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment D (high-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment A (low-dose CL-108) - Treatment C (low-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0858</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment B (high-dose CL-108) - Treatment D (high-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.2877</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment A (low-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment B (high-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emin: Treatment C (low-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emin: Treatment D (high-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Emin: Treatment A (low-dose CL-108) - Treatment C (low-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.1130</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Emin: Treatment B (high-dose CL-108) - Treatment D (high-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0575</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emin: Treatment A (low-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emin: Treatment B (high-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive Effects: Emax of High VAS in Treatment Phase</title>
        <description>High VAS measures the positive effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so'). For VAS assessment, pre-dose (baseline) value was subtracted from each post-dose value prior to calculation of the pharmacodynamic (PD) parameter. Emax is the largest effect score between 0 to 8 hours.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours (post-dose)</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 22.5 mg/975 mg/37.5 mg</title>
            <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 37.5 mg/1625 mg/62.5 mg</title>
            <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: M366 22.5 mg/975 mg</title>
            <description>M366 22.5 mg/975 mg tablet by mouth</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: M366 37.5 mg/1625 mg</title>
            <description>M366 37.5 mg/1625 mg tablet by mouth</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: Placebo</title>
            <description>Placebo 0 mg tablet by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Effects: Emax of High VAS in Treatment Phase</title>
          <description>High VAS measures the positive effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so'). For VAS assessment, pre-dose (baseline) value was subtracted from each post-dose value prior to calculation of the pharmacodynamic (PD) parameter. Emax is the largest effect score between 0 to 8 hours.</description>
          <population>ITT population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.9" spread="29.05"/>
                    <measurement group_id="O2" value="71.8" spread="26.07"/>
                    <measurement group_id="O3" value="54.6" spread="28.41"/>
                    <measurement group_id="O4" value="67.5" spread="22.76"/>
                    <measurement group_id="O5" value="5.4" spread="12.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment C (low-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment D (high-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment A (low-dose CL-108) - Treatment C (low-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.4025</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment B (high-dose CL-108) - Treatment D (high-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.3184</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment A (low-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment B (high-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive Effects: TA_AUE of High VAS in Treatment Phase</title>
        <description>TA_AUE is AUE0-8hr divided by time from dosing to the actual time of the 8-hour post-dose assessment using the trapezoidal rule.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours (post-dose)</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 22.5 mg/975 mg/37.5 mg</title>
            <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 37.5 mg/1625 mg/62.5 mg</title>
            <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: M366 22.5 mg/975 mg</title>
            <description>M366 22.5 mg/975 mg tablet by mouth</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: M366 37.5 mg/1625 mg</title>
            <description>M366 37.5 mg/1625 mg tablet by mouth</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: Placebo</title>
            <description>Placebo 0 mg tablet by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Effects: TA_AUE of High VAS in Treatment Phase</title>
          <description>TA_AUE is AUE0-8hr divided by time from dosing to the actual time of the 8-hour post-dose assessment using the trapezoidal rule.</description>
          <population>ITT population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.055" spread="2.8942"/>
                    <measurement group_id="O2" value="27.850" spread="21.6226"/>
                    <measurement group_id="O3" value="36.363" spread="21.0716"/>
                    <measurement group_id="O4" value="24.500" spread="20.8024"/>
                    <measurement group_id="O5" value="32.050" spread="20.7004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment C (low-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment D (high-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment A (low-dose CL-108) - Treatment C (low-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.2628</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment B (high-dose CL-108) - Treatment D (high-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.2262</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment A (low-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment B (high-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive Effects: Emax of Good Effects VAS in Treatment Phase</title>
        <description>Good drug effects VAS measures the positive effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so'). Emax is the largest effect score between 0.5 to 8 hours post-dose.</description>
        <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 22.5 mg/975 mg/37.5 mg</title>
            <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 37.5 mg/1625 mg/62.5 mg</title>
            <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: M366 22.5 mg/975 mg</title>
            <description>M366 22.5 mg/975 mg tablet by mouth</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: M366 37.5 mg/1625 mg</title>
            <description>M366 37.5 mg/1625 mg tablet by mouth</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: Placebo</title>
            <description>Placebo 0 mg tablet by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Effects: Emax of Good Effects VAS in Treatment Phase</title>
          <description>Good drug effects VAS measures the positive effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so'). Emax is the largest effect score between 0.5 to 8 hours post-dose.</description>
          <population>ITT population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="15.06"/>
                    <measurement group_id="O2" value="59.3" spread="29.42"/>
                    <measurement group_id="O3" value="68.3" spread="25.99"/>
                    <measurement group_id="O4" value="52.5" spread="29.35"/>
                    <measurement group_id="O5" value="62.2" spread="23.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment C (low-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment D (high-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment A (low-dose CL-108) - Treatment C (low-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.1839</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment B (high-dose CL-108) - Treatment D (high-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.1751</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment A (low-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment B (high-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive Effects: TA_AUE of Good Effects VAS in Treatment Phase</title>
        <description>TA_AUE is AUE0-8hr divided by time from dosing to the actual time of the 8-hour post-dose assessment using the trapezoidal rule.</description>
        <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 22.5 mg/975 mg/37.5 mg</title>
            <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 37.5 mg/1625 mg/62.5 mg</title>
            <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: M366 22.5 mg/975 mg</title>
            <description>M366 22.5 mg/975 mg tablet by mouth</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: M366 37.5 mg/1625 mg</title>
            <description>M366 37.5 mg/1625 mg tablet by mouth</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: Placebo</title>
            <description>Placebo 0 mg tablet by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Effects: TA_AUE of Good Effects VAS in Treatment Phase</title>
          <description>TA_AUE is AUE0-8hr divided by time from dosing to the actual time of the 8-hour post-dose assessment using the trapezoidal rule.</description>
          <population>ITT population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.108" spread="22.0759"/>
                    <measurement group_id="O2" value="34.894" spread="20.5885"/>
                    <measurement group_id="O3" value="25.541" spread="23.1053"/>
                    <measurement group_id="O4" value="29.327" spread="19.7001"/>
                    <measurement group_id="O5" value="1.140" spread="2.9074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment C (low-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment D (high-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment A (low-dose CL-108) - Treatment C (low-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.4013</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment B (high-dose CL-108) - Treatment D (high-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0736</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment A (low-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment B (high-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Negative Effects: Emax of Bad Effects VAS in Treatment Phase</title>
        <description>Bad effects VAS measures the negative effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so'). Emax is the largest effect score between 0.5 to 8 hrs.</description>
        <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 22.5 mg/975 mg/37.5 mg</title>
            <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 37.5 mg/1625 mg/62.5 mg</title>
            <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: M366 22.5 mg/975 mg</title>
            <description>M366 22.5 mg/975 mg tablet by mouth</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: M366 37.5 mg/1625 mg</title>
            <description>M366 37.5 mg/1625 mg tablet by mouth</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: Placebo</title>
            <description>Placebo 0 mg tablet by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Negative Effects: Emax of Bad Effects VAS in Treatment Phase</title>
          <description>Bad effects VAS measures the negative effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so'). Emax is the largest effect score between 0.5 to 8 hrs.</description>
          <population>ITT population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="21.89"/>
                    <measurement group_id="O2" value="30.1" spread="29.35"/>
                    <measurement group_id="O3" value="20.1" spread="20.61"/>
                    <measurement group_id="O4" value="36.1" spread="30.39"/>
                    <measurement group_id="O5" value="2.4" spread="9.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment C (low-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment D (high-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment A (low-dose CL-108) - Treatment C (low-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.2223</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment B (high-dose CL-108) - Treatment D (high-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.1638</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment A (low-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0041</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment B (high-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Negative Effects: TA_AUE of Bad Effects VAS in Treatment Phase</title>
        <description>TA_AUE is AUE0-8hr divided by time from dosing to the actual time of the 8-hour post-dose assessment using the trapezoidal rule.</description>
        <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 22.5 mg/975 mg/37.5 mg</title>
            <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 37.5 mg/1625 mg/62.5 mg</title>
            <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: M366 22.5 mg/975 mg</title>
            <description>M366 22.5 mg/975 mg tablet by mouth</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: M366 37.5 mg/1625 mg</title>
            <description>M366 37.5 mg/1625 mg tablet by mouth</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: Placebo</title>
            <description>Placebo 0 mg tablet by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Negative Effects: TA_AUE of Bad Effects VAS in Treatment Phase</title>
          <description>TA_AUE is AUE0-8hr divided by time from dosing to the actual time of the 8-hour post-dose assessment using the trapezoidal rule.</description>
          <population>ITT population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.487" spread="10.5253"/>
                    <measurement group_id="O2" value="12.535" spread="16.0605"/>
                    <measurement group_id="O3" value="7.171" spread="9.8243"/>
                    <measurement group_id="O4" value="13.830" spread="14.9453"/>
                    <measurement group_id="O5" value="0.217" spread="0.9084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment C (low-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment D (high-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment A (low-dose CL-108) - Treatment C (low-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.2706</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment B (high-dose CL-108) - Treatment D (high-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.5507</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment A (low-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0047</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment B (high-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sedative and Other Effects: Emin of Alertness/Drowsiness VAS in Treatment Phase</title>
        <description>Alertness/Drowsiness VAS measures the sedative effects. It is scored using a 100 mm bipolar VAS anchored in the center with a neutral anchor of 'neither drowsy nor alert' (score of 50 mm), on the left with 'very drowsy' (score of 0 mm) and on the right with 'very alert' (score of 100 mm). Alertness/Drowsiness VAS was calculated by subtracting pre-dose (baseline) value from each post-dose value. Emin is the smallest effect score between 0 to 8 hours post-dose.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours (post-dose)</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 22.5 mg/975 mg/37.5 mg</title>
            <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 37.5 mg/1625 mg/62.5 mg</title>
            <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: M366 22.5 mg/975 mg</title>
            <description>M366 22.5 mg/975 mg tablet by mouth</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: M366 37.5 mg/1625 mg</title>
            <description>M366 37.5 mg/1625 mg tablet by mouth</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: Placebo</title>
            <description>Placebo 0 mg tablet by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Sedative and Other Effects: Emin of Alertness/Drowsiness VAS in Treatment Phase</title>
          <description>Alertness/Drowsiness VAS measures the sedative effects. It is scored using a 100 mm bipolar VAS anchored in the center with a neutral anchor of 'neither drowsy nor alert' (score of 50 mm), on the left with 'very drowsy' (score of 0 mm) and on the right with 'very alert' (score of 100 mm). Alertness/Drowsiness VAS was calculated by subtracting pre-dose (baseline) value from each post-dose value. Emin is the smallest effect score between 0 to 8 hours post-dose.</description>
          <population>ITT population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" spread="18.27"/>
                    <measurement group_id="O2" value="20.2" spread="16.44"/>
                    <measurement group_id="O3" value="33.3" spread="17.46"/>
                    <measurement group_id="O4" value="27.9" spread="18.29"/>
                    <measurement group_id="O5" value="47.9" spread="15.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emin: Treatment C (low-dose M366)  Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emin: Treatment D (high-dose M366)  Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Emin: Treatment A (low-dose CL-108) - Treatment C (low-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0014</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Emin: Treatment B (high-dose CL-108) - Treatment D (high-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0080</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emin: Treatment A (low-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emin: Treatment B (high-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sedative and Other Effects: TA_AUE of Alertness/Drowsiness VAS in Treatment Phase</title>
        <description>Alertness/Drowsiness VAS measures the sedative effects. It is scored using a 100 mm bipolar VAS anchored in the center with a neutral anchor of 'neither drowsy nor alert' (score of 50 mm), on the left with 'very drowsy' (score of 0 mm) and on the right with 'very alert' (score of 100 mm). Alertness/Drowsiness VAS was calculated by subtracting pre-dose (baseline) value from each post-dose value. TA_AUE is AUE0-8hr divided by time from dosing to the actual time of the 8-hour post-dose assessment using trapezoidal rule.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours (post-dose)</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 22.5 mg/975 mg/37.5 mg</title>
            <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 37.5 mg/1625 mg/62.5 mg</title>
            <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: M366 22.5 mg/975 mg</title>
            <description>M366 22.5 mg/975 mg tablet by mouth</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: M366 37.5 mg/1625 mg</title>
            <description>M366 37.5 mg/1625 mg tablet by mouth</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: Placebo</title>
            <description>Placebo 0 mg tablet by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Sedative and Other Effects: TA_AUE of Alertness/Drowsiness VAS in Treatment Phase</title>
          <description>Alertness/Drowsiness VAS measures the sedative effects. It is scored using a 100 mm bipolar VAS anchored in the center with a neutral anchor of 'neither drowsy nor alert' (score of 50 mm), on the left with 'very drowsy' (score of 0 mm) and on the right with 'very alert' (score of 100 mm). Alertness/Drowsiness VAS was calculated by subtracting pre-dose (baseline) value from each post-dose value. TA_AUE is AUE0-8hr divided by time from dosing to the actual time of the 8-hour post-dose assessment using trapezoidal rule.</description>
          <population>ITT population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.103" spread="14.4192"/>
                    <measurement group_id="O2" value="-16.919" spread="17.3774"/>
                    <measurement group_id="O3" value="-6.751" spread="13.8670"/>
                    <measurement group_id="O4" value="-8.737" spread="15.7482"/>
                    <measurement group_id="O5" value="-0.348" spread="6.8048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment C (low-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0024</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment D (high-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment A (low-dose CL-108) - Treatment C (low-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0037</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment B (high-dose CL-108) - Treatment D (high-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment A (low-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment B (high-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sedative and Other Effects: Emax of Any Effects VAS in Treatment Phase</title>
        <description>Any drug effects VAS measures other subjective effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so'). Emax is the largest effect score between 0.5 to 8 hours post-dose.</description>
        <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 22.5 mg/975 mg/37.5 mg</title>
            <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 37.5 mg/1625 mg/62.5 mg</title>
            <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: M366 22.5 mg/975 mg</title>
            <description>M366 22.5 mg/975 mg tablet by mouth</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: M366 37.5 mg/1625 mg</title>
            <description>M366 37.5 mg/1625 mg tablet by mouth</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: Placebo</title>
            <description>Placebo 0 mg tablet by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Sedative and Other Effects: Emax of Any Effects VAS in Treatment Phase</title>
          <description>Any drug effects VAS measures other subjective effects experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (0 mm = 'definitely not') to 'extremely' (100 mm = 'definitely so'). Emax is the largest effect score between 0.5 to 8 hours post-dose.</description>
          <population>ITT population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.4" spread="26.02"/>
                    <measurement group_id="O2" value="71.9" spread="25.85"/>
                    <measurement group_id="O3" value="55.4" spread="27.11"/>
                    <measurement group_id="O4" value="68.9" spread="21.01"/>
                    <measurement group_id="O5" value="7.4" spread="15.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment C (low-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment D (high-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment A (low-dose CL-108) - Treatment C (low-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0630</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment B (high-dose CL-108) - Treatment D (high-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.4436</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment A (low-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emax: Treatment B (high-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sedative and Other Effects: TA_AUE of Any Effects VAS in Treatment Phase</title>
        <description>TA_AUE is AUE0-8hr divided by time from dosing to the actual time of the 8-hour post-dose assessment using the trapezoidal rule.</description>
        <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 22.5 mg/975 mg/37.5 mg</title>
            <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 37.5 mg/1625 mg/62.5 mg</title>
            <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: M366 22.5 mg/975 mg</title>
            <description>M366 22.5 mg/975 mg tablet by mouth</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: M366 37.5 mg/1625 mg</title>
            <description>M366 37.5 mg/1625 mg tablet by mouth</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: Placebo</title>
            <description>Placebo 0 mg tablet by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Sedative and Other Effects: TA_AUE of Any Effects VAS in Treatment Phase</title>
          <description>TA_AUE is AUE0-8hr divided by time from dosing to the actual time of the 8-hour post-dose assessment using the trapezoidal rule.</description>
          <population>ITT population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.720" spread="21.4816"/>
                    <measurement group_id="O2" value="38.504" spread="20.2062"/>
                    <measurement group_id="O3" value="26.371" spread="20.7356"/>
                    <measurement group_id="O4" value="34.030" spread="19.3426"/>
                    <measurement group_id="O5" value="1.537" spread="3.7125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment C (low-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment D (high-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment A (low-dose CL-108) - Treatment C (low-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.2335</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment B (high-dose CL-108) - Treatment D (high-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.1808</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment A (low-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment B (high-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Measures: Change From Baseline in Choice Reaction Time (CRT) in Treatment Phase</title>
        <description>CRT is a computerized 5-choice reaction time test in which the subject must press and hold down a touchscreen button at the bottom of the screen. A yellow spot appeared inside one of 5 yellow circles at the top of the screen. Subjects were to respond to the spot as quickly as they could by letting go of the button and touching the circle where the yellow spot appeared. This was repeated for 30 trials. Lower scores indicate better performance.</description>
        <time_frame>0 (Baseline, pre-dose), 1, 2, 4, 8 and 24 hours (post-dose)</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 22.5 mg/975 mg/37.5 mg</title>
            <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 37.5 mg/1625 mg/62.5 mg</title>
            <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: M366 22.5 mg/975 mg</title>
            <description>M366 22.5 mg/975 mg tablet by mouth</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: M366 37.5 mg/1625 mg</title>
            <description>M366 37.5 mg/1625 mg tablet by mouth</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: Placebo</title>
            <description>Placebo 0 mg tablet by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Measures: Change From Baseline in Choice Reaction Time (CRT) in Treatment Phase</title>
          <description>CRT is a computerized 5-choice reaction time test in which the subject must press and hold down a touchscreen button at the bottom of the screen. A yellow spot appeared inside one of 5 yellow circles at the top of the screen. Subjects were to respond to the spot as quickly as they could by letting go of the button and touching the circle where the yellow spot appeared. This was repeated for 30 trials. Lower scores indicate better performance.</description>
          <population>ITT population.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Predose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.0" spread="103.15"/>
                    <measurement group_id="O2" value="51.9" spread="22.52"/>
                    <measurement group_id="O3" value="51.2" spread="16.83"/>
                    <measurement group_id="O4" value="56.8" spread="28.83"/>
                    <measurement group_id="O5" value="55.0" spread="19.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hrs post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="104.21"/>
                    <measurement group_id="O2" value="9.8" spread="23.32"/>
                    <measurement group_id="O3" value="8.4" spread="24.48"/>
                    <measurement group_id="O4" value="11.1" spread="46.97"/>
                    <measurement group_id="O5" value="3.9" spread="34.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hrs post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7" spread="160.21"/>
                    <measurement group_id="O2" value="45.5" spread="81.23"/>
                    <measurement group_id="O3" value="24.8" spread="93.63"/>
                    <measurement group_id="O4" value="21.2" spread="55.12"/>
                    <measurement group_id="O5" value="8.8" spread="27.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hrs post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4" spread="155.96"/>
                    <measurement group_id="O2" value="38.3" spread="74.27"/>
                    <measurement group_id="O3" value="11.0" spread="32.97"/>
                    <measurement group_id="O4" value="7.9" spread="27.71"/>
                    <measurement group_id="O5" value="5.1" spread="20.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hrs post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="104.99"/>
                    <measurement group_id="O2" value="29.0" spread="56.17"/>
                    <measurement group_id="O3" value="4.9" spread="30.03"/>
                    <measurement group_id="O4" value="9.0" spread="45.69"/>
                    <measurement group_id="O5" value="4.9" spread="30.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hrs post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.6" spread="103.86"/>
                    <measurement group_id="O2" value="4.9" spread="35.28"/>
                    <measurement group_id="O3" value="16.7" spread="70.86"/>
                    <measurement group_id="O4" value="6.3" spread="46.15"/>
                    <measurement group_id="O5" value="4.1" spread="29.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Errors (Any Errors) in CRT Test in Treatment Phase</title>
        <description>CRT is a computerized 5-choice reaction time test in which the subject must press and hold down a touchscreen button at the bottom of the screen. A yellow spot appeared inside one of 5 yellow circles at the top of the screen. Subjects were to respond to the spot as quickly as they could by letting go of the button and touching the circle where the yellow spot appeared. This was repeated for 30 trials. Lower scores indicate better performance. CRT also measures error scores and response accuracy. Any Errors is a combination of incorrect location errors, inaccurate response errors, no response errors, and premature errors.</description>
        <time_frame>0 (Baseline, pre-dose), 1, 2, 4, 8 and 24 hours (post-dose)</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 22.5 mg/975 mg/37.5 mg</title>
            <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 37.5 mg/1625 mg/62.5 mg</title>
            <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: M366 22.5 mg/975 mg</title>
            <description>M366 22.5 mg/975 mg tablet by mouth</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: M366 37.5 mg/1625 mg</title>
            <description>M366 37.5 mg/1625 mg tablet by mouth</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: Placebo</title>
            <description>Placebo 0 mg tablet by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Errors (Any Errors) in CRT Test in Treatment Phase</title>
          <description>CRT is a computerized 5-choice reaction time test in which the subject must press and hold down a touchscreen button at the bottom of the screen. A yellow spot appeared inside one of 5 yellow circles at the top of the screen. Subjects were to respond to the spot as quickly as they could by letting go of the button and touching the circle where the yellow spot appeared. This was repeated for 30 trials. Lower scores indicate better performance. CRT also measures error scores and response accuracy. Any Errors is a combination of incorrect location errors, inaccurate response errors, no response errors, and premature errors.</description>
          <population>ITT population.</population>
          <units>Error per msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Predose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.86"/>
                    <measurement group_id="O2" value="0.4" spread="0.90"/>
                    <measurement group_id="O3" value="0.5" spread="0.87"/>
                    <measurement group_id="O4" value="0.8" spread="1.09"/>
                    <measurement group_id="O5" value="0.90" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hrs post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.29"/>
                    <measurement group_id="O2" value="0.1" spread="1.28"/>
                    <measurement group_id="O3" value="0.97" spread="0.16"/>
                    <measurement group_id="O4" value="1.21" spread="0.20"/>
                    <measurement group_id="O5" value="0.70" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hrs post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.48"/>
                    <measurement group_id="O2" value="0.9" spread="1.45"/>
                    <measurement group_id="O3" value="0.1" spread="1.18"/>
                    <measurement group_id="O4" value="0.1" spread="1.33"/>
                    <measurement group_id="O5" value="0.2" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hrs post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.30"/>
                    <measurement group_id="O2" value="1.4" spread="2.15"/>
                    <measurement group_id="O3" value="0.1" spread="1.26"/>
                    <measurement group_id="O4" value="-0.1" spread="1.36"/>
                    <measurement group_id="O5" value="0.1" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hrs post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.95"/>
                    <measurement group_id="O2" value="0.9" spread="2.11"/>
                    <measurement group_id="O3" value="0.1" spread="0.94"/>
                    <measurement group_id="O4" value="0.0" spread="1.21"/>
                    <measurement group_id="O5" value="0.1" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hrs post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.49"/>
                    <measurement group_id="O2" value="-0.1" spread="0.92"/>
                    <measurement group_id="O3" value="0.5" spread="1.12"/>
                    <measurement group_id="O4" value="-0.1" spread="0.91"/>
                    <measurement group_id="O5" value="0.1" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pupillometry: Maximum Pupil Constriction (MPC)</title>
        <description>Pupillometry assessments measured change in pupil size (miosis) as an indicator of opioid pharmacological properties. Pupil diameter was measured using electronic pupillometer. Measurements were collected under mesopic lighting conditions. For each subject, every effort was made to use the same eye for all assessments throughout the study. MPC is calculated as smallest observed pupil diameter - baseline pupil diameter.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours (post-dose)</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 22.5 mg/975 mg/37.5 mg</title>
            <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 37.5 mg/1625 mg/62.5 mg</title>
            <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: M366 22.5 mg/975 mg</title>
            <description>M366 22.5 mg/975 mg tablet by mouth</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: M366 37.5 mg/1625 mg</title>
            <description>M366 37.5 mg/1625 mg tablet by mouth</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: Placebo</title>
            <description>Placebo 0 mg tablet by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Pupillometry: Maximum Pupil Constriction (MPC)</title>
          <description>Pupillometry assessments measured change in pupil size (miosis) as an indicator of opioid pharmacological properties. Pupil diameter was measured using electronic pupillometer. Measurements were collected under mesopic lighting conditions. For each subject, every effort was made to use the same eye for all assessments throughout the study. MPC is calculated as smallest observed pupil diameter - baseline pupil diameter.</description>
          <population>ITT population</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.51" spread="0.852"/>
                    <measurement group_id="O2" value="3.15" spread="0.783"/>
                    <measurement group_id="O3" value="2.34" spread="0.852"/>
                    <measurement group_id="O4" value="2.75" spread="0.717"/>
                    <measurement group_id="O5" value="0.39" spread="0.537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>MPC: Treatment C (low-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Treatment D: M366 37.5 mg/1625 mg, Treatment E: Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MPC: Treatment A (low-dose CL-108) - Treatment C (low-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.1268</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>MPC: Treatment B (high-dose CL-108) - Treatment D (high-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0014</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>MPC: Treatment A (low-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>MPC: Treatment B (high-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pupillometry: TA_AUE of MPC in Treatment Phase</title>
        <description>TA_AUE is AUE0-8hr divided by time from dosing to the actual time of the 8-hour post-dose assessment using the trapezoidal rule.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours (post-dose)</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 22.5 mg/975 mg/37.5 mg</title>
            <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 37.5 mg/1625 mg/62.5 mg</title>
            <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: M366 22.5 mg/975 mg</title>
            <description>M366 22.5 mg/975 mg tablet by mouth</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: M366 37.5 mg/1625 mg</title>
            <description>M366 37.5 mg/1625 mg tablet by mouth</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: Placebo</title>
            <description>Placebo 0 mg tablet by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Pupillometry: TA_AUE of MPC in Treatment Phase</title>
          <description>TA_AUE is AUE0-8hr divided by time from dosing to the actual time of the 8-hour post-dose assessment using the trapezoidal rule.</description>
          <population>ITT population</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.565" spread="0.7042"/>
                    <measurement group_id="O2" value="2.355" spread="0.7394"/>
                    <measurement group_id="O3" value="1.317" spread="0.7014"/>
                    <measurement group_id="O4" value="1.888" spread="0.5855"/>
                    <measurement group_id="O5" value="-0.153" spread="0.3308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment C (low-dose M366)  Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment D (high-dose M366) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment A (low-dose CL-108)  Treatment C (low-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0120</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment B (high-dose CL-108)  Treatment D (high-dose M366)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment A (low-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>TA_AUE0-8hr: Treatment B (high-dose CL-108) - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to visit 3 (Follow up) for Dose Selection phase and Up to Day 24 (Follow up) for Treatment phase</time_frame>
      <desc>Total 12 subjects in Dose Selection and 40 subjects in Treatment Phase are enrolled and received at least 1 dose of study drug and were included in the Safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dose Selection AA: CL-108 15 mg/650 mg/25 mg</title>
          <description>CL-108 15 mg/650 mg/25 mg tablet by mouth</description>
        </group>
        <group group_id="E2">
          <title>Dose Selection BB: CL-108 22.5 mg/975 mg/37.5 mg</title>
          <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
        </group>
        <group group_id="E3">
          <title>Dose Selection CC: CL-108 30 mg/1300 mg/50 mg</title>
          <description>CL-108 30 mg/1300 mg/50 mg tablet by mouth</description>
        </group>
        <group group_id="E4">
          <title>Dose Selection CC: CL-108 37.5 mg/1625 mg/62.5 mg</title>
          <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
        </group>
        <group group_id="E5">
          <title>Dose Selection EE: Placebo</title>
          <description>Placebo 0 mg tablet by mouth</description>
        </group>
        <group group_id="E6">
          <title>Treatment AA: CL-108 22.5 mg/975 mg/37.5 mg</title>
          <description>CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth</description>
        </group>
        <group group_id="E7">
          <title>Treatment BB: CL-108 37.5 mg/1625 mg/62.5 mg</title>
          <description>CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth</description>
        </group>
        <group group_id="E8">
          <title>Treatment CC: M366 22.5 mg/975 mg</title>
          <description>M366 22.5 mg/975 mg tablet by mouth</description>
        </group>
        <group group_id="E9">
          <title>Treatment DD: M366 37.5 mg/1625 mg</title>
          <description>M366 37.5 mg/1625 mg tablet by mouth</description>
        </group>
        <group group_id="E10">
          <title>Treatment EE: Placebo</title>
          <description>Placebo 0 mg tablet by mouth</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="34" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="28" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="31" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="14" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling Hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Feeling of Relaxation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Disturbance in Attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Euphoric Mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Bruxism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abnormal Dreams</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="23" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="17" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pruritus Generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Commercial Officer</name_or_title>
      <organization>Charleston Laboratories, Inc.</organization>
      <phone>561-748-2007</phone>
      <email>cliregulatory@charlestonlabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

